|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
On September 27, 2018, the United States Food and Drug Administration (FDA) approved dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
|
31050691 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or L858R mutation usually respond to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), whereas T790M mutation and exon 20 insertion are frequently resistant to EGFR-TKIs.
|
31425965 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The L858R one-point mutation in exon 21 in EGFR is the most prevalent in NSCLC.
|
30593826 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer.
|
31516600 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Adult patients with stage IIIB/IV EGFR Mut+ NSCLC (exon 19 deletion or exon 21 L858R mutation) who had received first-line systemic therapy between 2011 and 2016 were included.
|
30608948 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The FLAURA trial established osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung cancer (NSCLC) with sensitizing <i>EGFR</i> mutations, namely exon 19 deletion and L858R.
|
30875928 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The antiproliferative activity of a dual PI3K/mTOR inhibitor BEZ235 was examined by the WST-1 assay and the soft agar colony-formation assay in 2 normal cell lines and 12 NSCLC cell lines: 6 expressing wild-type EGFR and 6 expressing EGFR with activating mutations, including exon 19 deletions, and L858R and T790 M point mutations.
|
31262325 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Finally, we evaluated the concordance between plasma and tumour tissues by simultaneously detecting EGFR L858R by ddPCR and LNA-dPNA PCR clamp in 132 tissues and matched plasma samples from patients with NSCLC.
|
30663747 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Exon 19 deletions and exon 21 L858R substitutions are the most common mutations, accounting for approximately 90% mutations in NSCLC; these are termed classic mutations and result in high sensitivity to tyrosine kinase inhibitors (TKIs).
|
31367543 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the entire assessable population of 4465 EGFR-mutant NSCLC patients, significant interactions with PFS were found for gender (males vs. females; pooled ratio of the PFS-HRs = 1.2; 95% CI 1.12-1.56), smoking history (smokers vs. non-smokers; pooled ratio of the PFS-HRs = 1.26; 95% CI 1.05-1.51), and type of EGFR mutation (patients with exon 21 L858R mutation vs. exon 19 deletion; pooled ratio of the PFS-HRs = 1.39; 95% CI 1.18-1.63).
|
31466227 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
EGFR)-targeted drugs have been the first-line treatment for patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC), especially exon 19 deletions and L858R mutation in exon 21.
|
31686847 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
It is approved for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, and for patients with T790M-positive advanced NSCLC whose disease has progressed on or after EGFR-TKI therapy.
|
30875094 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Fifty-six distinct uncommon <i>EGFR</i> mutations other than L858R, exon19del, exon20ins, or T790M were identified in 18.9% of patients with <i>EGFR</i>-mutant NSCLC.
|
30902917 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In our case, a non-small cell lung cancer patient developed intrinsic EGFR-TKI resistance and was then confirmed to simultaneously harbor an L858R mutation and ROS1 rearrangement.
|
30775851 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The L858R one-point mutation in exon 21 in EGFR is the most prevalent in NSCLC.
|
30593826 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The FLAURA trial established osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung cancer (NSCLC) with sensitizing <i>EGFR</i> mutations, namely exon 19 deletion and L858R.
|
30875928 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab.
|
31393548 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
On September 27, 2018, the United States Food and Drug Administration (FDA) approved dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
|
31050691 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Secondary acquired mutant EGFR (L858R-T790M) overexpressed NSCLC forms one of the prevalent form of resistant NSCLC.
|
31078412 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
L858R point mutation is the most common oncogenic mutation in EGFR tyrosine kinase domain in patients with EGFR-mutated NSCLC.
|
31116768 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
To assess the utility of the <b>cobas</b> EGFR Mutation Test, with tissue and plasma, for first-line osimertinib therapy for patients with <i>EGFR</i>-mutated (<i>EGFR</i>m; Ex19del and/or L858R) advanced or metastatic non-small cell lung cancer (NSCLC) from the FLAURA study (NCT02296125).
|
31439584 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer.
|
31516600 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here we report a case of emergent <i>MET</i> amplification detected in a tumor sample from a patient with NSCLC harboring EGFR L858R mutation after disease progression on erlotinib.
|
30881166 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
EGFR)-targeted drugs have been the first-line treatment for patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC), especially exon 19 deletions and L858R mutation in exon 21.
|
31686847 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Two main categories of epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) patients are deletions in exon 19 and L858R in exon 21.
|
31327643 |
2019 |